Bayer files riociguat for CTEPH and PAH in US and EU
This article was originally published in Scrip
Bayer has filed for approval in the US and EU for its oral soluble guanylate cyclase (sGC) stimulator riociguat for two forms of pulmonary hypertension. The company had planned the filings for the first half of 2013 following positive results in the two indications, chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PAH), both rare but life-threatening diseases. While there are approved therapies for PAH, the prognosis is poor. There are no currently approved drugs available for CTEPH.